Oxford University Hospital
Welcome,         Profile    Billing    Logout  
 16 Trials 
30 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Collins, Graham
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
AVENuE, NCT03617666: Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

Active, not recruiting
2
49
Europe, RoW
Avelumab, Bavencio
University College, London, Pfizer
Hodgkin Lymphoma
07/22
05/25
ANIMATE, NCT03337919: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
78
Europe
Nivolumab, Opdivo®
University College, London, Bristol-Myers Squibb
Hodgkin Lymphoma
03/23
02/26
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen Inc.
Peripheral T-cell Lymphoma
05/24
12/25
P+R-ICE, NCT05221645: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting
2
65
Europe
Pembrolizumab, KEYTRUDA, Rituximab, MabThera, Ifosfamide, Carboplatin, Etoposide
University of Southampton, Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma
05/26
12/26
RATiFY, NCT05627115: Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

Not yet recruiting
2
80
NA
Tislelizumab, AVD, Radiotherapy, Response-adapted incorporation of tislelizumab
University College, London, BeiGene
Hodgkin Lymphoma
10/28
10/28
NCT05463263: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Recruiting
1/2
180
Europe, US
STP938
Step Pharma, SAS
Lymphoma, B-Cell, Lymphoma, T-Cell
12/25
12/25
Betts, Tim R
SyncAV, NCT04100148: Post-Market Trial

Active, not recruiting
N/A
1686
Europe, Canada, Japan, US, RoW
SyncAV programmed ON, Fixed AV delay
Abbott Medical Devices
Congestive Heart Failure
06/25
12/25
PRAETORIAN-DFT, NCT03495297: A Randomised Trial of S-ICD Implantation With and Without Defibrillation Testing

Active, not recruiting
N/A
965
Europe, US
ommitence of defibrillation testing
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Boston Scientific Corporation
Ventricular Arrythmia
10/24
10/24
ICONIC-M, NCT05564793: Improving CRT Outcome With Non-Invasive Cardiac Mapping

Recruiting
N/A
330
Europe
Pre-implantation planning, ECGI mapping, Post-implantation assessment
EP Solutions SA
Heart Failure With Reduced Ejection Fraction
09/25
06/26
DISCOVER, NCT03893331: AcQMap® Global Registry of Procedural and Long-term Clinical Outcomes (AcQMap Registry)

Terminated
N/A
479
Europe
AcQMap System
Acutus Medical
Ablation of Arrhythmia's
11/23
11/23
Chamberlin, Paul
IMPROVE-DiCE, NCT04826159: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)

Hourglass Oct 2023 - Dec 2023 : Part 2 data from IMPROVE-DiCE trial in patients with cardiomyopathy
Checkmark Data from IMPROVE-DiCE trial in patients with cardiomyopathy at ESC 2022
Aug 2022 - Aug 2022: Data from IMPROVE-DiCE trial in patients with cardiomyopathy at ESC 2022
Recruiting
2
50
Europe
IMB-1018972
Imbria Pharmaceuticals, Inc., University of Oxford
Type 2 Diabetes, Diabetic Cardiomyopathies, HFpEF - Heart Failure With Preserved Ejection Fraction
03/24
03/24
NCT04306237: A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

Suspended
2
640
US
IMB-1018972, Placebo oral tablet
Imbria Pharmaceuticals, Inc.
Refractory Angina
02/25
04/25
Rinaldi, Simon
NCT03943589: A Study of Imlifidase in Patients With Guillain-Barré Syndrome

Completed
2
30
Europe
Imlifidase, Hansa Medical-Immunoglobulin G degrading enzyme of Streptococcus pyogenes (HMED-IdeS), IdeS, IgG endopeptidase
Hansa Biopharma AB
Guillain-Barré Syndrome (GBS)
02/24
02/24
ARDA+, NCT05405361 / 2021-004998-32: A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Multifocal Motor Neuropathy

Active, not recruiting
2
51
Europe, Canada, US
ARGX-117, Placebo
argenx, argenx BV
Multifocal Motor Neuropathy (MMN)
09/26
09/26
iMMersioN, NCT05988073: A Prospective Longitudinal Study in Adults with Multifocal Motor Neuropathy

Recruiting
N/A
150
Europe, Canada, Japan, US, RoW
argenx
Multifocal Motor Neuropathy
11/25
11/25
Collins, Angela
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Recruiting
2/3
148
Europe
Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib
University College, London, Janssen-Cilag Ltd.
Waldenstrom Macroglobulinemia
03/30
03/30
PembroWM, NCT03630042 / 2018-001767-23: Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Completed
2
17
Europe
Pembrolizumab, Rituximab
University College, London, Merck Sharp & Dohme LLC
Waldenstrom Macroglobulinemia
09/21
02/24
Uberoi, Raman
TiGER, NCT04246463: Terumo Aortic Global Endovascular Registry

Recruiting
N/A
1000
Europe, US
Thoracic, Abdominal, Custom Device, Illiac Artery
Vascutek Ltd., Bolton Medical
Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
11/29
11/30
Talks, Katherine
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Recruiting
3
150
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor
11/28
11/28
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Recruiting
2
120
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
03/26
06/26
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Recruiting
N/A
200
Europe, Canada, US, RoW
No Intervention
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
11/24
11/24
Obaji, Samya
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Recruiting
3
150
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor
11/28
11/28
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Recruiting
2
120
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
03/26
06/26
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Recruiting
N/A
200
Europe, Canada, US, RoW
No Intervention
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
11/24
11/24
Murali, Kesavan
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Recruiting
2/3
148
Europe
Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib
University College, London, Janssen-Cilag Ltd.
Waldenstrom Macroglobulinemia
03/30
03/30
Shapiro, Susan
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Recruiting
3
150
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor
11/28
11/28
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Recruiting
2
120
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
03/26
06/26
NCT06648837: Microvisk Continuous Blood Donation Study

Not yet recruiting
N/A
2500
Europe
Venepuncture, Collection of relevant information
Microvisk Technologies Ltd
Pulmonary Embolism (Diagnosis), Deep Vein Thrombosis, Atrial Fibrillation (AF)
10/29
11/29

Download Options